Claims for Patent: 8,822,423

Summary for Patent: 8,822,423

Title:	Affinity peptides toward infliximab
Abstract:	We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.
Inventor(s):	Ryan; Daphne Ann Salick (Manalapan, NJ), Kehoe; John (Wayne, PA), Wheeler; John (Downingtown, PA), Yang; Chunlin (Belle Mead, NJ), Creasey; Abla (Morristown, NJ)
Assignee:	Janssen Biotech, Inc. (Horsham, PA)
Application Number:	13/474,056
Patent Claims:	1. An affinity peptide toward infliximab having the peptide sequence of SEQ ID NO: 2 or SEQ ID NO: 10. 2. A controlled release device comprising an affinity biomatrix, further comprising a polymer and an affinity peptide toward infliximab having the peptide sequence of SEQ ID NO: 2 or SEQ ID NO: 10, and infliximab. 3. The controlled release device of claim 2, wherein the polymer is a natural polymer. 4. The controlled release device of claim 3, wherein the natural polymer is selected from the group consisting of collagen, elastin, keratin, silk, polysaccharides, GAGs, and combinations thereof. 5. The controlled release device of claim 4 wherein the polysaccharide is selected from the group consisting of starch, pectin, cellulose, alkyl cellulose, alkylhydroxyalkyl cellulose, hydroxyalkyl cellulose, cellulose sulfate, salts of carboxymethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate, cross-linked alginate/alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, carboxymethyl chitosan, chitosan, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratan sulfate, carrageenans, chitosan, starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid, polyglucuronic acid, and polyglucuronic acid. 6. The controlled release device of claim 3, wherein the natural polymer is collagen. 7. The controlled release device of claim 3, wherein the natural polymer is decellularized tissue selected from the group consisting of skin, periosteum, perichondrium, synovium, fascia, mesenter, bone and sinew. 8. The controlled release device of claim 6, wherein the collagen is in the form of sponges, particles, injectable gels, injectable liquids, membranes, films, fibers and fiber based scaffolds. 9. A kit comprising an affinity biomatrix, further comprising a polymer and an affinity peptide toward infliximab having the peptide sequence of SEQ ID NO: 2 or SEQ ID NO: 10, and infliximab.

Details for Patent 8,822,423

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2039-03-29